Handelsavisen
prelaunch
Companies ›Healthcare ›4127.TWO
41
4127.TWO — TPEx Pharmaceuticals

Tien Liang Biotech Co Ltd

$39,10
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
0,00 %
Op margin
-3,2 %
ROE
-2,2 %
Net margin
-2,0 %
Debt / equity
1,26
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

Tien Liang Biotech Co Ltd is a pharmaceutical company engaged in the development and production of pharmaceutical products.

Business. Tien Liang Biotech Co Ltd (4127.TWO) is a pharmaceutical company engaged in the development and sale of healthcare products. The firm is headquartered in Taiwan and is primarily listed on the Taiwan Premium Exchange (TPEx). Specific details regarding its operating segments and geographic revenue mix are not disclosed.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
-2,2 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 4127.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 4127.TWO. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Tien Liang Biotech Co Ltd (4127.TWO) is a pharmaceutical company engaged in the development and sale of healthcare products. The firm is headquartered in Taiwan and is primarily listed on the Taiwan Premium Exchange (TPEx). Specific details regarding its operating segments and geographic revenue mix are not disclosed.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    Tien Liang Biotech has a debt-to-equity ratio of 1.26, indicating a moderate level of leverage, and a current ratio of 0.4, suggesting potential liquidity constraints. The company's free cash flow is negative at -23.37 million TWD, and its operating cash flow is 19.23 million TWD, highlighting a mismatch between operating performance and capital outflows.

    The company's profitability is weak, with a return on equity of -2.16% and a return on assets of -0.87%. These figures fall below the typical expectations for a pharmaceutical firm, indicating underperformance relative to industry norms.

    Tien Liang Biotech's revenue is concentrated in a single jurisdiction, as disclosed segments and geographic exposure are not specified in the available data. This lack of diversification may expose the company to regional economic or regulatory risks.

    The company's growth trajectory is unclear, as no specific revenue growth rates or outlooks are provided in the available data. However, the negative operating and net income suggest operational challenges that could hinder future expansion.

    The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after accounting for total debt, which could limit its ability to fund operations or investments without external financing.

    Recent events, including filings and transcripts, are not detailed in the available data, making it difficult to assess any recent strategic or operational developments that may impact the company's performance.

    Key takeaways
    • Tien Liang Biotech has a high debt-to-equity ratio and a weak current ratio, indicating liquidity and leverage concerns.
    • The company's profitability metrics are negative, suggesting operational inefficiencies or declining sales.
    • Revenue concentration in a single jurisdiction may increase exposure to regional risks.
    • The company's growth outlook is uncertain due to a lack of detailed financial projections.
    • Liquidity risk is moderate, and dilution risk is low, but the negative net cash position could constrain operations.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $39,10
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    $474.0M
    Net cashⓘ
    -$475.7M
    Current ratioⓘ
    0.4
    Debt / equityⓘ
    1.3
    ROAⓘ
    -0.9%
    ROEⓘ
    -2.2%
    Cash conversionⓘ
    -188.0%
    CapEx / revenueⓘ
    -4.5%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-3,1 %Below median
    Net Margin-2,0 %Below median
    ROE-2,2 %Below median
    Capex / Rev-4,5 %Above median
    D/E1,26Bottom quartile
    Cash Conv-1,88Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Tien Liang Biotech Co Ltd Market data — financials · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    4127.TWOCanonical
    TPEx · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage